Summary
Cannot evaluate alignment because no FDA-approved prescribing information (label text/sections) was provided. All statements are therefore unverified against the label.
Category Scores
Accurate Statements
Unsupported Statements
Opdivo (nivolumab) uses the body’s immune system to help fight cancer.
No FDA label excerpts were provided to verify this claim.
Opdivo blocks a specific checkpoint protein called PD-1 (programmed death-1).
No FDA label excerpts were provided to verify this claim.
By inhibiting PD-1, Opdivo helps T cells stay active against tumor cells.
No FDA label excerpts were provided to verify this claim.
Opdivo targets PD-1.
No FDA label excerpts were provided to verify this claim.
Other immune checkpoint medicines may target PD-L1 or CTLA-4.
No FDA label excerpts were provided to verify this claim.
Opdivo is used in multiple cancer types.
No FDA label excerpts were provided to verify this claim.
Opdivo is used in cancers where the PD-1/PD-L1 pathway is relevant to tumor immune evasion.
No FDA label excerpts were provided to verify this claim.
The exact approvals for Opdivo depend on the cancer type and setting.
No FDA label excerpts were provided to verify this claim.
Some uses of Opdivo depend on biomarker testing commonly including PD-L1.
No FDA label excerpts were provided to verify this claim.
Some uses of Opdivo do not require biomarker testing.
No FDA label excerpts were provided to verify this claim.
Whether a specific test is needed depends on the specific cancer type and treatment line.
No FDA label excerpts were provided to verify this claim.
Opdivo can be used alone depending on the indication and clinical setting.
No FDA label excerpts were provided to verify this claim.
Opdivo can be used with other therapies such as chemotherapy depending on the indication and clinical setting.
No FDA label excerpts were provided to verify this claim.
Opdivo can be used with other immunotherapies depending on the indication and clinical setting.
No FDA label excerpts were provided to verify this claim.
Because Opdivo activates immune responses, it can cause immune-related side effects.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect the skin.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect the intestines.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect the lungs.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect the liver.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect the endocrine glands.
No FDA label excerpts were provided to verify this claim.
Immune-related side effects from Opdivo can affect other systems.
No FDA label excerpts were provided to verify this claim.
Contradictions
Important Omissions
FDA label text for indications, dosing/administration, contraindications, boxed warning/warnings, drug interactions, adverse reactions, monitoring, and use in specific populations.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
Because no prescribing information was provided, potentially material labeling-required safety information (e.g., boxed warning, contraindications, specific adverse reactions/monitoring, and population-specific cautions) cannot be verified against the AI statements.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Cannot Evaluate
Primary Issue
No FDA-approved prescribing information excerpts were provided for comparison.
Suggested Improvement
Resend the AI-generated response and provide relevant FDA label excerpts with section numbers (e.g., INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS/BOXED WARNING, DRUG INTERACTIONS, ADVERSE REACTIONS, and USE IN SPECIFIC POPULATIONS) so each claim can be checked for support or contradiction.